Plus   Neg

Pfizer Invests $120 Million In Four Clinical-stage Biotech Companies In H2 2020 - Quick Facts

Pfizer Inc. (PFE) announced Tuesday that it invested a total of $120 million in four clinical-stage biotech companies during the second half of 2020 as part of the Pfizer Breakthrough Growth Initiative (PBGI).

Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer's scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest to Pfizer.

The first four investments of new program created to support clinical-stage biotechnology companies including companies focused on oncology, rare disease, and inflammation & immunology.

Pfizer invested $10 million in Vancouver, BC-based clinical-stage pharmaceutical company ESSA Pharma (EPIX), $25 million in Cambridge, Mass.-based clinical-stage immuno-oncology company Trillium Therapeutics (TRIL), $25 million in Cambridge, Mass.-based privately held clinical-stage company Vedanta Biosciences, and $60 million in Bedford, Mass.-based clinical-stage genetic medicines company Homology Medicines (FIXX).

Separately, Vedanta Biosciences announced that it intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021. Topline Phase 1 study data showed VE202 was generally safe and well-tolerated at all doses and demonstrated durable and dose-dependent colonization.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year. Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow.
Follow RTT